Cargando…

Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study

OBJECTIVES: Large population-based studies on the incidence and outcome of non-small cell lung cancer (NSCLC) are lacking in mainland China. This study aimed to investigate the NSCLC incidence, demographic features and survival as well as factors affecting survival of patients with NSCLC in Shanghai...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Heng, Shao, Zhen-Yi, Xiao, Yuan-Yuan, Xie, Zhi-Hui, Chen, Wen, Xie, Hua, Qin, Guo-You, Zhao, Nai-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691760/
https://www.ncbi.nlm.nih.gov/pubmed/26700282
http://dx.doi.org/10.1136/bmjopen-2015-009419
_version_ 1782407190807576576
author Fan, Heng
Shao, Zhen-Yi
Xiao, Yuan-Yuan
Xie, Zhi-Hui
Chen, Wen
Xie, Hua
Qin, Guo-You
Zhao, Nai-Qing
author_facet Fan, Heng
Shao, Zhen-Yi
Xiao, Yuan-Yuan
Xie, Zhi-Hui
Chen, Wen
Xie, Hua
Qin, Guo-You
Zhao, Nai-Qing
author_sort Fan, Heng
collection PubMed
description OBJECTIVES: Large population-based studies on the incidence and outcome of non-small cell lung cancer (NSCLC) are lacking in mainland China. This study aimed to investigate the NSCLC incidence, demographic features and survival as well as factors affecting survival of patients with NSCLC in Shanghai. DESIGN: Prospective observational cohort study. SETTING: Baseline information was collected from Shanghai Health Information Network, which is based on the Health Information Systems from all the comprehensive hospitals and specialist hospitals qualified for cancer diagnosis in the Shanghai metropolitan area. PARTICIPANTS: All NSCLC cases identified from the database between 2011 and 2013 were recruited (15 020 patients). MAIN RESULTS: The crude and age-adjusted incidences of NSCLC were 54.20 per 100 000 people (55.90 per 100 000 for men, 52.39 per 100 000 for women) and 39.05 per 100 000 people (41.43 per 100 000 for men and 37.13 per 100 000 for women), respectively. The median survival time was 22.7 months (95% CI 21.8 to 24.2 months) with an overall 1-year survival rate of 71.8% (95% CI 69.8% to 73.8%). The 1-year survival rate was 96.5% (95% CI 94.0% to 98.6%) in patients with stage I NSCLC, 89.1% (95% CI 83.3% to 94.9%) in patients with stage II NSCLC, 78.8% (95% CI 74.1% to 83.5%) in patients with stage IIIa NSCLC and 58.9% (95% CI 56.1% to 61.7%) in patients with stage IIIb/IV NSCLC. Multivariate analysis showed surgical resection (HR=0.607, 95% CI 0.511 to 0.722) and chemotherapy (HR=0.838, 95% CI 0.709 to 0.991) significantly improved survival. Factors associated with poor survival included older age, male sex, larger tumour size, lymph node metastasis, distant metastasis and squamous cell carcinoma. CONCLUSIONS: A higher incidence and better survival rates for patients with NSCLC were identified when compared with previously published studies, which may provide evidence on the incidence and survival of NSCLC in China.
format Online
Article
Text
id pubmed-4691760
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46917602015-12-30 Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study Fan, Heng Shao, Zhen-Yi Xiao, Yuan-Yuan Xie, Zhi-Hui Chen, Wen Xie, Hua Qin, Guo-You Zhao, Nai-Qing BMJ Open Oncology OBJECTIVES: Large population-based studies on the incidence and outcome of non-small cell lung cancer (NSCLC) are lacking in mainland China. This study aimed to investigate the NSCLC incidence, demographic features and survival as well as factors affecting survival of patients with NSCLC in Shanghai. DESIGN: Prospective observational cohort study. SETTING: Baseline information was collected from Shanghai Health Information Network, which is based on the Health Information Systems from all the comprehensive hospitals and specialist hospitals qualified for cancer diagnosis in the Shanghai metropolitan area. PARTICIPANTS: All NSCLC cases identified from the database between 2011 and 2013 were recruited (15 020 patients). MAIN RESULTS: The crude and age-adjusted incidences of NSCLC were 54.20 per 100 000 people (55.90 per 100 000 for men, 52.39 per 100 000 for women) and 39.05 per 100 000 people (41.43 per 100 000 for men and 37.13 per 100 000 for women), respectively. The median survival time was 22.7 months (95% CI 21.8 to 24.2 months) with an overall 1-year survival rate of 71.8% (95% CI 69.8% to 73.8%). The 1-year survival rate was 96.5% (95% CI 94.0% to 98.6%) in patients with stage I NSCLC, 89.1% (95% CI 83.3% to 94.9%) in patients with stage II NSCLC, 78.8% (95% CI 74.1% to 83.5%) in patients with stage IIIa NSCLC and 58.9% (95% CI 56.1% to 61.7%) in patients with stage IIIb/IV NSCLC. Multivariate analysis showed surgical resection (HR=0.607, 95% CI 0.511 to 0.722) and chemotherapy (HR=0.838, 95% CI 0.709 to 0.991) significantly improved survival. Factors associated with poor survival included older age, male sex, larger tumour size, lymph node metastasis, distant metastasis and squamous cell carcinoma. CONCLUSIONS: A higher incidence and better survival rates for patients with NSCLC were identified when compared with previously published studies, which may provide evidence on the incidence and survival of NSCLC in China. BMJ Publishing Group 2015-12-23 /pmc/articles/PMC4691760/ /pubmed/26700282 http://dx.doi.org/10.1136/bmjopen-2015-009419 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Oncology
Fan, Heng
Shao, Zhen-Yi
Xiao, Yuan-Yuan
Xie, Zhi-Hui
Chen, Wen
Xie, Hua
Qin, Guo-You
Zhao, Nai-Qing
Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
title Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
title_full Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
title_fullStr Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
title_full_unstemmed Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
title_short Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
title_sort incidence and survival of non-small cell lung cancer in shanghai: a population-based cohort study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691760/
https://www.ncbi.nlm.nih.gov/pubmed/26700282
http://dx.doi.org/10.1136/bmjopen-2015-009419
work_keys_str_mv AT fanheng incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT shaozhenyi incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT xiaoyuanyuan incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT xiezhihui incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT chenwen incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT xiehua incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT qinguoyou incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy
AT zhaonaiqing incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy